Clinical trial to compare the analgesic efficacy of selected Traditional Medicine Formulations (TMF-06,-24,-25) on experimentally induced pain in human subjects

Forty clinically healthy volunteers participated in the study aimed to evaluate the therapeutic efficacy of three Traditional Medicine Formulations (TMF-06, TMF-24 and TMF-25) on experimentally-induced cold compressor stimulation pain. The rationale underlying the study is that these formulations have beenproduced locally and used extensively as standard analgesics for pain relief at the Traditional Medicine Hospitals and dispensaries as well as through self-medication over-the-counter-durgs by the local community for many years but has yet received little investigative attention regarding efficacy and sefety. The study was a placebo controlled double-blind, complete cross-over single dose design using aspirin (acetyl salicylate) as positive standard and was evaluated on three basic pain response parameters namely, pain threshold, pain tolerance and pain sensitivity range. All three formulations showed a significant analgesic efficacy (p < 0.01) when compared to placebo (TMF-25 > TMF-24 > TMF-60). No, adverse effects were noted even when given at maximum recomended dose. It was concluded dose. It was concluded that the three TMFs can be used as an alternative to aspirin for the symptomatic relief of mild to moderate pain.

Clinical trial to determine the antidiarrhoeal potential of traditional medicine formulations TMFs-16, TMF-35a and TMF-43

Clinical trial to determine the therapeutic efficacy of three Traditional Medicine Formulations, claimed to have antidiarrhoeal action, were studied on 150 acute diarrhoeal patients admitted to the Infectious Diseases Hospital, Yangon. TMF-16 was found to possess a good antidiarrhoeal action with the antidiarrhoeal index (ADI) of 28.71 percent, which is approximately equal to that of the standard drug, loparamide which had the ADI of 27.94 percent. TMF-35a also possess a mild to moderate antidiarrhoeal action (ADI = 21.5 percent), but TMF-43 showed little or no antidiarrhoeal action (ADI = 9.64 percent). The cllinical significance of the study is that both TMF-16 and loparamide were found to reduce the stool output as well as the amount of fluid replacement required. TMF-16 is well tolerated, available locally and cheaply, and thus, may prove beneficial in the symptomatic relief of non-specific acute diarrhoea.